How to Vet a GP-Led Continuation Fund Before You Commit Capital

Roughly half of all secondaries capital now flows into GP-led continuation funds, according to Adams Street Partners, which puts continuation vehicles at close to 50% of its 2026 secondaries deployment. If you're a limited partner in a private equity fund, that number should change how you read your next capital call notice. Continuation funds aren't a niche workaround anymore. They're a standard exit tool, and your general partner will likely bring you one within the next few years. The question isn't whether you'll face this decision. It's whether you'll know how to evaluate it when it lands in your inbox.

What a Continuation Fund Actually Is

A GP-led continuation fund is a transaction where your fund's general partner (GP) creates a brand-new fund vehicle, sells one or more of the original fund's portfolio companies into it, and offers you two choices: roll your stake into the new vehicle at a negotiated valuation, or cash out at that same price. The GP typically stays on as manager of both the old fund and the new one. That's the built-in tension. The same person setting the sale price for the asset is also the person who wants to keep managing it, and who may earn a new round of management fees and carried interest (the GP's share of profits above a return hurdle) once the new fund is capitalized.

This isn't automatically bad. Continuation funds exist because some portfolio companies need more time or more capital than the original fund's life allows. A GP running a 10-year fund might hold a business in year eight that's still compounding value nicely, but the fund's term is ending and investors expect liquidity. A continuation fund lets the GP extend the hold, bring in fresh capital from new investors, and give existing LPs a choice instead of a forced sale into a rushed process. Done well, it can be a genuine win for everyone. Done poorly, it's a related-party transaction dressed up as a liquidity option, and you're on the wrong side of an information gap.

Why LPs Face a Real Decision, Not a Formality

When a continuation fund transaction lands on your desk, you're not just approving a routine fund extension. You're being asked to judge whether the sale price is fair, whether the process that produced it was fair, and whether staying in is better than taking cash today. Those are three separate questions, and GPs sometimes bundle them into one rushed vote.

Here's the conflict in plain terms. The GP negotiates the price at which the asset moves from the old fund to the new one. If the price is too low, existing LPs who cash out lose value while the GP's new fund (and the new investors backing it) get a bargain. If the price is too high, LPs who roll over are stuck holding an overvalued asset while the GP books a win for the old fund's track record. Either way, the GP has a hand on both sides of the table. That's exactly why the Institutional Limited Partners Association, known as ILPA, built a specific framework for these deals, and why law firms like Skadden now describe continuation funds as "mainstream, not marginal" in their 2026 client guidance.

ILPA's Guidance: Conflicts, Fairness Opinions, and the Status Quo Option

ILPA published its first continuation fund guidance in 2023 and is updating it again in 2026. You don't need to read the full document, but you do need to understand four concepts it introduced, because they now function as the industry's baseline for what a fair process looks like.

The first is the Limited Partner Advisory Committee, or LPAC, a group of LP representatives who review conflicts of interest on behalf of the full investor base. Under ILPA's 2023 guidance, the LPAC should get at least 10 business days to review a proposed continuation fund transaction before voting on any conflict waiver. If your GP is asking the LPAC to vote within 48 hours of disclosure, that's not a compressed process, that's a process designed to prevent real scrutiny.

The second is the fairness opinion, an independent third-party valuation of the asset being sold, produced by a firm with no stake in the outcome. Houlihan Lokey, which leads this market alongside firms like Evercore, found in its 2024 Continuation Fund Study that fairness opinions have become close to universal in these deals. That shift accelerated after the SEC's private fund adviser reforms effectively required an independent fairness or valuation opinion before an advisor-led secondary transaction can close. If your GP isn't producing one, ask why.

The third is the election timeline. ILPA's guidance says LPs should get no less than 30 calendar days to decide whether to roll or sell, with full, unrestricted access to the data room, meaning the same diligence materials new investors in the continuation fund are seeing. Some more recent legal alerts, including one from ArentFox Schiff, note a push toward 30 business days, not calendar days, which is meaningfully longer. Either way, a two-week deadline to decide on a multi-million dollar reinvestment is a red flag by itself.

The fourth, and the one most LPs have never heard of, is the status quo option, sometimes called "remain in place." This means the original fund simply continues on its existing terms for LPs who don't want to roll into a new vehicle with a new fee structure and a reset carry clock. ILPA's proposed 2026 guidance, detailed in a Mayer Brown client alert from July 2026, adds "remain in place" as one of five standard election options LPs should be offered, on what's called a comply-or-explain basis, meaning the GP either offers it or has to justify in writing why it didn't. The underlying principle ILPA calls the "no worse off" standard: an LP who elects to sell should end up no worse off, economically, than if the transaction had never happened. If a GP's term sheet doesn't include some version of a status quo option, ask directly why not.

Also worth noting: ILPA launched a standardized Continuation Fund Disclosure Template in January 2026, per Skadden's April 2026 insight. If your GP is still sending you a bespoke, hard-to-parse disclosure packet instead of something built on that template, that's a process signal worth flagging to your LPAC representative.

The Due-Diligence Checklist

Before you sign anything, work through this list. Treat any answer that dodges the question as a data point in itself.

• How long did the LPAC actually have to review the transaction before voting on the conflict waiver? (Benchmark: at least 10 business days per ILPA's 2023 guidance.)
• How many calendar or business days do LPs get to elect roll versus sell, and does that window start when full data room access is granted, or before? (Benchmark: no less than 30 days, with some guidance pushing for 30 business days.)
• Who prepared the fairness opinion, and does that firm have any other financial relationship with the GP or the incoming continuation fund investors?
• Is a status quo or "remain in place" option available? If not, what is the GP's written justification for excluding it?
• What are the fee and carry terms in the new continuation fund, and how do they compare to the original fund? Is the carry clock (the point at which the GP starts earning a profit share) resetting to zero, effectively making you pay twice for the same gains?
• Is a new hurdle rate being applied, and if so, is it lower or higher than the original fund's hurdle?
• Who are the new investors buying into the continuation fund, and did they participate in setting the price, or was the price set before they were brought in?
• Has the GP or any of its principals invested personal capital into the continuation fund at the same price and terms offered to rolling LPs?
• Was the LPAC given the ability to negotiate terms, or only to approve or reject a fully baked deal?
• Does the disclosure packet follow ILPA's January 2026 standardized Continuation Fund Disclosure Template, or is it a custom format that's harder to benchmark against other deals you've seen?
• What happens to your capital and your rights if you take no action by the election deadline? (Default-to-roll provisions without an explicit opt-in are a red flag.)

Watch especially for three patterns. First, a compressed timeline that gives the LPAC or the broader LP base materially less time than ILPA's benchmarks, especially when paired with pressure to vote before a stated "hard deadline" that seems to move. Second, the total absence of a status quo option combined with a vague or missing explanation, since ILPA's 2026 guidance explicitly expects a comply-or-explain answer here. Third, fee and carry reset terms that let the GP earn a second full carry on gains it already generated once, particularly when the new hurdle rate is lower than the old one. Any one of these should slow you down. Two together should make you call outside counsel.

Jeff's Take: When to Roll and When to Walk

I'll give you the version I'd want if I were sitting on your LPAC. A continuation fund is worth rolling into when four things are true at once: the fairness opinion comes from a credible, independent shop with no other ties to the deal, the LPAC had real time and real leverage to negotiate rather than rubber-stamp, a status quo option exists so your decision to roll is genuinely voluntary, and the underlying business is one you'd want to own for another five years anyway, regardless of who's managing it. If all four hold, rolling can actually be the better economic outcome, because you avoid a forced sale at a moment that may not suit the asset's value curve, and you stay exposed to a company your GP knows better than any buyer would.

Walk away, or at least push hard for cash-out terms, when the process itself smells rushed. A GP who won't give the LPAC 10 business days, who can't explain why a status quo option isn't on the table, or who resets your carry clock without adjusting the hurdle to compensate, is optimizing for their own fee stream, not your outcome. Remember the American Infrastructure Funds case that Skadden's 2026 insight references: undisclosed conflicts in an asset transfer locked up investor capital for 11 extra years, ending in a 2023 SEC enforcement finding. That's the tail risk of skipping diligence on a deal that looked routine at the time. Nobody signs up for an 11-year lockup. They sign up for a "standard" continuation vote they didn't examine closely enough.

One more thing. Don't confuse a well-run process with a guaranteed good outcome, or a messy process with a guaranteed bad one. A clean, ILPA-compliant process with full disclosure and a real status quo option can still produce a valuation you think is too low, in which case cashing out is the right call even though nobody did anything wrong. Conversely, a GP with a slightly compressed timeline might still be offering you fair terms if you push back and get the extra two weeks. The checklist above isn't a pass/fail test. It's a way to separate the process question from the price question, so you're not making an emotional decision under an artificial deadline. If your fund documents give your LPAC a real seat at the table, use it. If they don't, or if your GP is treating LPAC input as a formality, that's information about how this GP will treat you the next time, continuation fund or not.

Author Disclosure: Jeff Barnes, MBA has no personal position in any company, fund, or platform named in this article. Angel Investors Network has no current commercial relationship with any party mentioned. AIN provides marketing and education services, not investment advice. Past performance does not guarantee future results. All investments involve risk, including loss of principal.